Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer

Nanoscale Research Letters

Volumn 7, Issue 1, 2012, Pages 1-11

  Qiu, Bo ^a,c   Ji, Minghui ^b   Song, Xiaosong ^c   Zhu, Yongqiang ^c   Wang, Zhongyuan ^c   Zhang, Xudong ^c   Wu, Shu ^c   Chen, Hongbo ^c   Mei, Lin ^c,d   Zheng, Yi ^c,d  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

^d Xili University Town   (China)

Author keywords

Cervical cancer; Docetaxel; Endostatin; Nanoparticles; TPGS b (PCL ran PGA)

Indexed keywords

CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; ELECTROPHORESIS; MAMMALS; MORPHOLOGY; NANOPARTICLES; POLYETHYLENES; TARGETED DRUG DELIVERY; TISSUE ENGINEERING; TUMORS;

BIODEGRADABLE NANOPARTICLE; CERVICAL CANCERS; CONFOCAL LASER SCANNING MICROSCOPY; DOCETAXEL; ENDOSTATINS; MULTIFUNCTIONAL CARRIERS; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATES; TPGS-B-(PCL-RAN-PGA);

LANTHANUM COMPOUNDS;

EID: 84875290399     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-7-666     Document Type: Article

References (34)

1. IARC: Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses, vol. 90. http://monographs.iarc.fr/.
2. WHO (World Health Organization): Human papillomaviruses. http://www. who. int/vaccine_research/ diseases/viral_cancers/en/index3.html.
3. Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53-61.
4. Winlaw DS: Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg 1997, 64:1204-1211.
5. Folkman J: Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 2007, 42:1-11.
6. Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006, 312:594-607.
7. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273-286.
8. Michael SO: Antiangiogenesis and vascular endothelial growth factor/ vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007, 69:S64-S66.
9. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
10. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
11. Herbst RS, Lee AT, Tran HT, Abbruzzese JL: Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 2001, 3:131-140.
12. Zhuang HQ, Yuan ZY: Process in the mechanisms of endostatin combined with radiotherapy. Cancer Letters 2009, 282:9-13.
13. Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 2007, 20:1439-1447.
14. Guinn BA, Mulherkar R: International progress in cancer gene therapy. Cancer Gene Ther 2008, 12:765-775.
15. Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007, 14:1057-1064.
16. Androic I, Krämer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K, Yuan J: Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8:391-401.
17. Gao Y, Liu XL: Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine 2011, 6:1017-1025.
18. Zhou J, Wu J, Hafdi N: PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) 2006, 22:2362-2364.
19. Mao SR, Sun W, Kissel T: Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010, 62:12-27.
20. Son S, Kim WJ: Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery. Biomaterials 2010, 31:133-143.
21. Blum JS, Saltzman WM: High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release 2008, 129:66-72.
22. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995, 92:7297-7301.
23. Zhu LP, Xing J, Wang QX, Kou L, Li C, Hu B, Wu ZW, Wang JJ, Xu GX: Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors. Eur J Pharmacol 2009, 617:23-27.
24. Huang L, Chen H, Zheng Y, Song X, Liu R, Liu K, Zeng X, Mei L: Nanoformulation of D-α-tocopheryl polyethylene glycol 1000 succinateb-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integr Biol 2011, 3:993-1002.
25. Kim JH, Park JS, Yang HN, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JM, Park KH: The use of biodegradable PLGA nanoparticles to mediate SOX9 gene delivery in human mesenchymal stem cells (hMSCs) and induce chondrogenesis. Biomaterials 2011, 32:268-278.
26. Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, Eisen HN, Heller J, Langer R, Putnam D: Molecularly engineered poly (ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004, 3:190-196.
27. Zolnik BS, Burgess DJ: Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 2007, 122:338-344.
28. Yin Y, Chen D, Qiao M, Wei X, Hu H: Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release 2007, 123:27-38.
29. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kwon GS: Doxorubicin-loaded poly(ethylene glycol)-poly (beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 2000, 64:143-153.
30. Lee AL, Wang Y, Cheng HY, Pervaiz S, Yang YY: The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30:919-927.
31. Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ: Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 2011, 31:4214-4222.
32. Wang L, Yao B, Li Q, Mei K, Xu JR, Li HX, Wang YS, Wen YJ, Wang XD, Yang HS, Li YH, Luo F, Wu Y, Liu YY, Yang L: Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models. Hum Gene Ther 2011, 22(9):1061-1069.
33. Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM: Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007, 4(3):465-474.
34. Dintaman JM, Silverman JA: Inhibition of P-glycoprotein by Dalphatocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999, 16:1550-1556.